BUZZ-Evommune soars after eczema therapy shows promise in mid-stage trial
I'm PortAI, I can summarize articles.
Evommune's shares surged 102.47% to $33.8 premarket after its experimental therapy, EVO301, successfully met the main goal in a mid-stage trial for moderate-to-severe atopic dermatitis. In a trial with 70 patients, 23% achieved clear or nearly clear skin compared to placebo. EVO301, an injectable drug targeting IL-18, showed significant reductions in eczema severity scores. The company is also exploring additional uses for EVO301, including ulcerative colitis. Despite this, the stock has declined 16% over the past year.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments